Good podcast? Give it some love!
Simon Wentworth
The Pharma Letter PodcastEpisodes
Episodes of The Pharma Letter Podcast
Mark All
Search Episodes...
This week we’re focusing on an area of clinical research that has been of great interest for a number of years, that is NASH, also known as MASH. It’s a high area of unmet medical need, with over 20 million diagnosed cases across Europe and the
This week we are speaking with the chief executive of British drug development company Ellipses Pharma. Founded in 2018 to create new cancer therapies, the firm is following a unique multimodal approach to clinical development, leveraging a var
In the world of outsourced clinical research, ICON is a big fish in a pond full of other increasingly big fish.In this episode of The Pharma Letter Podcast, we chat with the company’s chief commercial officer, George McMillan.Like many in the i
With an Accelerated nod for Aduhelm (aducanumab) and now full approval for Leqembi (lecanemab) in the USA, Biogen (Nasdaq: BIIB) and Eisai (TYO: 4523) have overturned decades of failure in Alzheimer’s.But at the annual meeting of the Alzheimer’
In the runup to the annual meeting of the Alzheimer’s Association, this week we are speaking with Michael Irizarry, deputy chief clinical officer at Eisai US.At the event in July, there will be plenty to discuss, with recent new data from Eli L
Set against a backdrop of foundering confidence in biotech stocks, the success of some companies incubated by Massachusetts-based Flagship Pioneering has been remarkable.Flagship has invested billions of dollars getting startups off the ground,
A draft of the European Commission’s ongoing review of pharmaceutical legislation has leaked, prompting a bitterly-worded reaction from drugmakers, which accuse legislators of “sabotaging” the industry.There is no doubt that the proposals repre
This week on The Pharma Letter Podcast, we are joined by Galapagos (Euronext: GLPG) chief executive Paul Stoffels.After an illustrious career as chief scientific officer at Johnson & Johnson (NYSE: JNJ), Dr Stoffels is ready for a new chapter i
The outcome of the recent midterm elections in the USA surprised many by returning a Democrat-led Senate, preventing Republicans from gaining control of the next Congress.Analysts, having expected a stronger showing for Republicans, put some of
*Partnered contentIn Boston, Massachusetts, one company is now making significant headway in the development of an innovative treatment for rare pediatric liver diseases.Led by president and chief executive officer Ron Cooper, Albireo (Nasdaq:
As President Joe Biden signs the Inflation Reduction Act into law, drugmakers in the USA are poring over the likely impact on drug prices, and how best to respond to its enactment.The legislation passed in the US Congress with Vice President Ka
For years, commentators have observed that drug prices in the USA are significantly higher than elsewhere in the world. Pointing to the high levels of innovation in the USA, a country where new drugs and biologics tend to get launched first, ar
Interest in the potential for artificial intelligence to transform different aspects of the drug discovery and development process is at an all-time high.According to industry analyst GlobalData, the number of AI deals in pharma has doubled in
With the approval of Aduhelm (aducanumab), the first new Alzheimer’s treatment in decades, people affected by dementia were given new hope that a breakthrough had finally arrived.A year later, the product is yet to gain traction in the USA, the
In recent years there has been an explosion of digital tools and platforms in the life sciences industry, designed to improve processes ranging from drug discovery and development, through to registration and commercialization.As with everythin
Companies developing microbiome-based treatments have garnered a lot of interest recently, following many years of uncertainty over the therapeutic potential of the approach.This has led to more money from venture capitalists, and increased val
At the national level, drug pricing continues to be a hot button issue for lawmakers, drugmakers and patients in the USA.For many years, successive administrations have proposed a range of regulatory reforms designed to contain what some regard
This week, we look at the potential impact of decentralized clinical trials.During the The COVID-19 pandemic, we have seen increased adoption of this kind of study, as part of a general movement towards greater use of innovative digital platfor
In this podcast, we discuss an exciting new collaboration between pharmaceutical majors in the field of AI.Around the world, ever increasing investments are being made in artificial intelligence, as drugmakers spy an opportunity to drive effici
In August 2020, Russia approved its homegrown coronavirus vaccine Sputnik V, months ahead of rival programs in the west.But despite the bleak pandemic outlook, there was no clamour in Europe or the USA to place orders, as scientists criticized
In the early days of the coronavirus pandemic, many drugmakers saw major share price declines as investors got to grips with the likely impact on prescribing, developing medicines, and supply chain interruptions.The second half of 2020 pointed
Patient empowerment is a hot topic in many areas of medicine. Particularly so for diseases that are more complex to manage, and present with symptoms that aren’t immediately obvious and which vary greatly among individuals.Multiple sclerosis (M
High-risk MDS, often referred to as preleukemia, is a chronic form of blood cancer with a significant level of unmet medical need.MDS is a complicated disease, presenting several obstacles to drug developers, and no new therapies have been appr
With all signs pointing to an M&A boom in late 2021 and throughout 2022, our guest will provide valuable insight into current and emerging trends in the biotech investing landscape.In this episode of The Pharma Letter Podcast, we speak with Lan
For many years, industry commentators have observed that there could be huge untapped therapeutic potential for psychedelics, should the correct development pathways be found.Investment in this area is now at an all-time high, with waves of neu
Join Podchaser to...
- Rate podcasts and episodes
- Follow podcasts and creators
- Create podcast and episode lists
- & much more
Unlock more with Podchaser Pro
- Audience Insights
- Contact Information
- Demographics
- Charts
- Sponsor History
- and More!
- Account
- Register
- Log In
- Find Friends
- Resources
- Help Center
- Blog
- API
Podchaser is the ultimate destination for podcast data, search, and discovery. Learn More
- © 2024 Podchaser, Inc.
- Privacy Policy
- Terms of Service
- Contact Us